Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved...
SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our",...
OVERLAND PARK, Kan.--(BUSINESS WIRE)--#CMSAlignedNetwork--Netsmart, an industry-leading provider of healthcare technology solutions and services for community-based care providers, announced its commitment...
VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / December 22, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC PINK:OVATF) ("Ovation"...
Telehealth Platform Offers Compounded GLP-1 Injections and Oral Tablets at $299/Month With No Contract as 100,000+ Patients Seek Affordable Semaglutide...
Investment to accelerate the growth of a post-acute care platform focused on reducing hospital readmissions and improving outcomesSAN DIEGO, Dec....
LONG BEACH, Calif. and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company")...
MURFREESBORO, TN / ACCESS Newswire / December 18, 2025 / National Health Investors, Inc. (NYSE:NHI) announced today that it has...
ANNAPOLIS, Md. and BOISE, Idaho, Dec. 18, 2025 /PRNewswire/ -- RXNT, a leading clinical EHR and Practice Management software company,...
ANNAPOLIS, Md. and BOISE, Idaho, Dec. 18, 2025 /PRNewswire/ -- RXNT, a leading clinical EHR and Practice Management software company,...
DefenCath® demonstrated a 72% reduction in CRBSI and 70% reduction in hospitalizations secondary to CRBSIBERKELEY HEIGHTS, N.J., Dec. 18, 2025...
DefenCath® demonstrated a 72% reduction in CRBSI and 70% reduction in hospitalizations secondary to CRBSIBERKELEY HEIGHTS, N.J., Dec. 18, 2025...
Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority...
Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority...
"Federal Marijuana Reform Is Coming-But FDA-Ready Companies Will Benefit the most" Duane Boise CEO MMJ International Holdings stated. WASHINGTON, DC...
ORANGE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at...
ORANGE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at...
ZeOmega believes that this designation underscores its differentiation in modernizing payer care management amid rising interoperability and AI-related regulatory demands...
Kazan will take Avalere Health's prestigious policy offering to new heights while Housman will infuse biopharma brands with evolving public...
Kazan will take Avalere Health's prestigious policy offering to new heights while Housman will infuse biopharma brands with evolving public...